Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6900

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6900). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve showing the proportion of patients with relapse over time (days) from randomization. The chart compares two treatment groups: Duloxetine and placebo, with Duloxetine showing a lower proportion of relapse over approximately 200 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between placebo and duloxetine 60/120 mg once daily. The x-axis indicates percent improvement in pain, ranging from >0 to 100%, and the y-axis shows the percentage of patients improved, from 0 to 100%. Two lines represent placebo and duloxetine treatment groups, with duloxetine generally showing a higher percentage of patients improved across increasing levels of pain improvement.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A Kaplan-Meier line graph showing the proportion of patients experiencing relapse over time from randomization to relapse in days. The chart compares treatment with Duloxetine versus placebo, where Duloxetine shows a consistently lower proportion of relapse over approximately 250 days.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, showing trends in pain improvement across varying thresholds.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The graph demonstrates trends of patient improvement across different pain relief levels.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph comparing percentage of patients improved against percent improvement in pain from baseline. It depicts data for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups, showing the relationship between pain improvement and patient response rates over a range of pain improvement percentages.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline, comparing Duloxetine at doses of 120 mg, 60 mg, 20 mg once daily, and a placebo. The graph illustrates patient response rates across different levels of pain improvement.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg once daily and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines are plotted: one for Duloxetine and one for placebo, showing a higher percentage of improvement with Duloxetine than placebo across various pain improvement percentages.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent pain improvement from >0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. The graph shows higher patient improvement percentages with Duloxetine over placebo across pain improvement levels.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line chart comparing the percentage of patients improved by placebo versus Duloxetine 60 mg once daily across different levels of percent improvement in pain from baseline. The x-axis shows percent improvement in pain (BOCF) from >0 to 100%, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. Duloxetine shows higher patient improvement percentages compared to placebo across most pain improvement levels, with vertical dashed lines at 30% and 50% improvement marks.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride depicted, showing fused rings including a naphthalene moiety and a thiophene ring, with an amine hydrochloride group.*

FDA Label Image

Label Image (Lbl500906900)

Duloxetine 30 mg delayed-release capsules label from A-S Medication Solutions. The label specifies oral capsules with 30 mg equivalent to 30 mg duloxetine hydrochloride USP, enteric-coated. The container holds 90 capsules, storage instructions include keeping at 77 degrees Fahrenheit. The label includes lot number and NDC 50090-6900.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.